Concurrent Treatment of Cardiovascular Disease in Peritoneal Dialysis (PD) patients. Multi-center Randomized Clinical Study with Aldosterone blockade (spironolactone) and Angiotensin Receptor Blocker (ARB) or Angiotensin-Converting-Enzyme Inhibitor (ACEI).

Concurrent Treatment of Cardiovascular Disease in Peritoneal Dialysis (PD) patients. Multi-center Randomized Clinical Study with Aldosterone blockade (spironolactone) and Angiotensin Receptor Blocker (ARB) or Angiotensin-Converting-Enzyme Inhibitor (ACEI). - MCS/AA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000492

Enrollment

160

Registered

2006-10-01

Start date

2006-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-Stage Renal Disease (ESRD) and Cardio-Vascular Disease (CVD)

Interventions

Spironolactorne No Spironolactorne

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Should be included all; NYHA I or II, continuing PD treatment less than 5 years, taken one of ARB or ACEI more than 3 months at least, and registration by the patients themselves

Exclusion criteria

Exclusion criteria: Should be excluded even if one of them would be positive; Patients under 18, older than 80. Patients with anemia whose Hb is less than 9 g/dl. Patients treated for more than 5 years after initiation of dialysis. Patients with heart failure of NYHA III, IV. Patients with pregnancy or the suspected. Patients treated with acid-base fluid dialysis.

Design outcomes

Primary

Measure	Time frame
Parameters of CVD, occurrence and/or augmentation of the other complications in peritoneal dialysis (PD) patients	—

Secondary

Measure	Time frame
residual renal functional examination, peritoneal functional examination	—

Countries

Japan

Contacts

Public ContactYasuhiko Ito

Nagoya University Nephrology and Renal Replacement Therapy

yasuito@med.nagoya-u.ac.jp052-744-2205

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026